Context Therapeutics (CNTX) Accumulated Expenses (2020 - 2026)
Context Therapeutics (CNTX) posted Accumulated Expenses of $3.9 million for Q1 2026, down 27.28% sequentially from $5.4 million in Q4 2025, and up 396.15% YoY from $787776.0 in Q1 2025.
Context Therapeutics (CNTX) Accumulated Expenses (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Accumulated Expenses for 7 years, with the latest figure at $3.9 million in Q1 2026.
- Quarterly Accumulated Expenses rose 396.15% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 396.15% YoY) and the FY2025 annual result came in at $5.4 million, up 352.1% from the prior year.
- Accumulated Expenses retreated to $3.9 million in Q1 2026 per CNTX's latest filing, from $5.4 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $5.4 million in Q4 2025 and troughed at $563058.0 in Q1 2024.
- A 5-year average of $2.1 million and a median of $2.0 million in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2026: Accumulated Expenses slumped 71.73% in 2024, then soared 396.15% in 2026.
- Over 5 years, Accumulated Expenses stood at $2.2 million in 2022, then declined by 18.39% to $1.8 million in 2023, then sank by 34.27% to $1.2 million in 2024, then soared by 352.1% to $5.4 million in 2025, then retreated by 27.28% to $3.9 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $3.9 million, $5.4 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.43 Mn |
| Mar 31, 2026 | 3.91 Mn |
| Dec 31, 2025 | 5.38 Mn |
| Sep 30, 2025 | 3.20 Mn |
| Jun 30, 2025 | 2.04 Mn |
| Mar 31, 2025 | 787,776.00 |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 992,832.00 |
| Mar 31, 2024 | 563,058.00 |
| Dec 31, 2023 | 1.81 Mn |
| Sep 30, 2023 | 2.78 Mn |
| Jun 30, 2023 | 2.56 Mn |
| Mar 31, 2023 | 1.99 Mn |
| Dec 31, 2022 | 2.22 Mn |
| Sep 30, 2022 | 2.44 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 1.21 Mn |
| Sep 30, 2021 | 1.33 Mn |